Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study
2022 · JTO Clinical and Research Reports · 9 citations
https://doi.org/10.1016/j.jtocrr.2022.100353